The team is led by Hugh Young Rienhoff, Jr., a physician with 25 years of experience in the field of biotechnology. The operational team provides broad oversight of clinical trials, quality and chemical manufacturing. Imago’s operational model facilitates the team’s management of CMC activities and clinical studies in Europe, Asia and North America in multiple therapeutic areas, notably hematology and oncology. Imago has established many collaborations with clinical investigators and scientists to continuously enhance the scientific foundation of our clinical programs.
Imago is developing pioneering medicines for the treatment of myeloproliferative diseases.